Is co‑amoxiclav (amoxicillin + clavulanic acid) safe to use during pregnancy?

Co-amoxiclav Safety in Pregnancy

Co-amoxiclav (amoxicillin + clavulanic acid) is generally safe to use during pregnancy and is classified as compatible throughout all trimesters, though it should be avoided in women at high risk of preterm delivery due to a very low risk of neonatal necrotizing enterocolitis. 1

Regulatory Classification and Safety Profile

Co-amoxiclav carries a TGA Category B1 and FDA Category B classification, indicating that studies in pregnant women have not demonstrated increased risk of fetal abnormalities 1. The FDA label specifically states that reproduction studies in pregnant rats and mice at doses up to 1,200 mg/kg/day (4.9 and 2.8 times the maximum human dose based on body surface area) revealed no evidence of harm to the fetus 2.

Clinical Evidence and Outcomes

Major Congenital Malformations

• Large population studies demonstrate no increased risk: A cohort study of 101,615 pregnancies with 6,041 first-trimester exposures to co-amoxiclav found no significant association with major malformations (adjusted relative risk 1.09,95% CI 0.98-1.20) 3

• Prospective controlled data support safety: A matched cohort of 191 women exposed to co-amoxiclav in the first trimester showed malformation rates of 1.9% versus 3% in controls (P=0.49), within expected baseline population risk 4

• Hungarian population surveillance: Analysis of 6,935 cases with congenital abnormalities versus 10,238 controls found no increased risk (OR 1.4,95% CI 0.9-2.0) 5

Specific Concerns to Address

Oral clefts: While there is theoretical concern about exposure during organogenesis being associated with oral clefts, the European Respiratory Society guidelines note this risk is "very low" 1. A systematic review identified one case-control study suggesting possible increased cleft palate risk, but cohort studies did not confirm major anomalies 6

Necrotizing enterocolitis (NEC): The single most important caveat is that co-amoxiclav is not recommended in women at risk of preterm delivery due to very low risk of necrotizing enterocolitis in the fetus 1. This concern originated from a 2001 trial on prophylactic antibiotics in preterm prelabor rupture of membranes, but subsequent studies between 2001-2008 did not confirm this finding 7. The FDA label acknowledges this single study reporting increased NEC risk in neonates when used prophylactically in women with premature rupture of membranes 2

Practical Prescribing Guidance

When to Use Co-amoxiclav in Pregnancy

Co-amoxiclav remains a first-line antibiotic option for pregnant women requiring treatment for bacterial infections, including:

• Respiratory tract infections 1
• Urinary tract infections (when susceptibility confirmed) 1
• Intra-abdominal infections in inflammatory bowel disease 1
• Surgical prophylaxis for cesarean section (though cefazolin preferred) 1

Key Clinical Decision Points

1. Assess preterm delivery risk: If the patient has risk factors for preterm delivery (e.g., preterm labor, premature rupture of membranes, cervical insufficiency), choose an alternative antibiotic such as cefuroxime or azithromycin 1

2. Timing considerations: Co-amoxiclav can be prescribed at any stage of pregnancy, including just before delivery, when clinically indicated and preterm delivery risk is low 7

3. No dose adjustment needed: Standard therapeutic doses are appropriate throughout pregnancy 2

Breastfeeding Compatibility

Co-amoxiclav is compatible with breastfeeding 1. Ampicillin-class antibiotics are excreted in breast milk, but this is not contraindicated 2. The main consideration is that systemic antibiotics in breast milk could cause falsely negative cultures in febrile infants or produce gastroenteritis due to alteration of intestinal flora 1

Common Pitfalls to Avoid

• Do not withhold necessary treatment: The FDA label emphasizes that while animal studies are not always predictive, the drug should be used during pregnancy "only if clearly needed" - but this must be balanced against the well-established risks of untreated maternal infection 2

• Do not confuse with amoxicillin alone: Plain amoxicillin carries TGA Category A classification, while co-amoxiclav is B1, but both are considered compatible in pregnancy 1

• Avoid in high-risk preterm scenarios: This is the single most important contraindication - specifically avoid prophylactic use in women with threatened preterm delivery 1, 2